Faron Pharmaceuticals Oy PDMR Shareholding (3448O)
May 16 2018 - 11:53AM
UK Regulatory
TIDMFARN
RNS Number : 3448O
Faron Pharmaceuticals Oy
16 May 2018
Faron Pharmaceuticals Oy
("Faron" or the "Company")
PDMR Dealing
TURKU - FINLAND, 16 May 2018 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, announces that on 16 May 2018 it was notified that on 15
May 2018 Dr Jonathan Knowles, a Non-Executive Director of Faron has
acquired 7,200 ordinary shares in Faron at an average price of
118.00 pence per ordinary share and 1,300 ordinary shares in Faron
at an average price of 116.97 pence per ordinary share.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
-------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
---- -------------------------------------------------------------------
a. Name Jonathan Knowles
----------------------------------------
2 Reason for
notification
---- ------------------------- ----------------------------------------
a. Position/Status Person discharging managerial
responsibilities
Non-Executive Director
---- ------------------------- ----------------------------------------
b. Initial notification/ Initial Notification
Amendment
---- ------------------------- ----------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
---- ------------------------- ----------------------------------------
b. LEI 7437009H31TO1DC0EB42
---- ------------------------- ----------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -------------------------------------------------------------------
a. Description Ordinary shares
of the financial
instrument, ISIN: FI4000153309
type of instrument
Identification
Code
---- ------------------------- ----------------------------------------
b. Nature of the Purchase of ordinary shares
transaction
---- ------------------------- ----------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
---- ------------------------- ---------------- -----------
118.00 GBPp 7,200
116.97 GBPp 1,300
----------------------------------------------------- -----------
d. Aggregated
information
8,500
- Aggregated
Volume GBP 10,016.61
- Price
---- ------------------------- ----------------------------------------
e. Date of the May 15, 2018
transaction
---- ------------------------- ----------------------------------------
f. Place of the Turku
transaction
---- ------------------------- ----------------------------------------
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's lead candidate Traumakine, to prevent vascular leakage
and organ failures, has completed a Phase III clinical trial in
Acute Respiratory Distress Syndrome ("ARDS"). An additional
European Phase II Traumakine trial is underway for the Rupture of
Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate
Clevegen is a ground breaking preclinical anti-Clever-1 antibody.
Clevegen has the ability to switch immune suppression to immune
activation in various conditions, with potential across oncology,
infectious disease and vaccine development. This novel
macrophage-directed immuno-oncology switch called Tumour Immunity
Enabling Technology ("TIET") may be used alone or in combination
with other immune checkpoint molecules for the treatment of cancer
patients. Faron is based in Turku, Finland. Further information is
available at www.faron.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSFEFMMFASEII
(END) Dow Jones Newswires
May 16, 2018 12:53 ET (16:53 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024